mortality/aging
|
• 40% of transgenic mice succumb to EAE compared to no non-transgenic littermates
|
nervous system
|
• 7/15 mice without EAE show typical myelinating/demyelinating lesions of optic neuritis
• mice with EAE show typical myelinating/demyelinating lesions of optic neuritis
• 55 and 78% of transgenic mice immunized with 100 and 10 ug of MOG 35-55 without PT, respectively, develop optic nerve lesions
|
|
• mice with or without EAE that display optic neuritis have myelinating/demyelinating lesions consisting of subpial and endoneurial mononuclear cell infiltrates with demyelination indicated by presence of foamy macrophages
|
|
• mice with optic neuritis have varying degrees of axonal injury and loss
|
demyelination
(
J:83278
)
|
• CNS tissues show myelin loss
|
vision/eye
blepharitis
(
J:83278
)
|
• mice without EAE develop superficial inflammation around the eyelids; this is unilateral and not observed in wild-type littermates during up to 1 year observation
|
|
• superficial eye lesions in mice without EAE are often associated with progressive atrophy of the eye
• 67% of mutants show these eye lesions compared to no wild-type
|
eyelid edema
(
J:83278
)
|
• mice without EAE show eyelid inflammation and eyelid swelling; this is unilateral and not observed in wild-type littermates during up to 1 year observation
|
|
• mice with or without EAE that display optic neuritis have myelinating/demyelinating lesions consisting of subpial and endoneurial mononuclear cell infiltrates with demyelination indicated by presence of foamy macrophages
|
immune system
|
• CD4/CD8 single positive ratio in thymus of transgenic mice is biased toward CD4+ compartment
• analysis shows a skewing toward CD4+ T cells in spleens as well
|
|
• spleen cells from naive mice produce high levels of IFN gamma in response to MOG 35-55
|
|
• 4% (3/72) of mice develop spontaneous EAE, indicated initially by a limp tail, followed by hindlimb paralysis between 2.5 and 5 months of age
• 55 and 78% of mice immunized with 100 and 10 ug of MOG 35-55 without PT, respectively, develop optic nerve lesions
• mice with disease have typical myelinating/demyelinating lesions
|
|
• transgenic mice immunized with MOG 35-55 + pertussis toxin (PT) develop more severe EAE than non-transgenic littermates, with earlier onset and greater clinical scores; 50% of mice develop associated optic neuritis also
• injection of PT alone induces clinical EAE in 39% and histological EAE in 56% of transgenics compared to no non-transgenic mice; 80% of mice develop associated optic neuritis also
|
|
• 7/15 mice without EAE show typical myelinating/demyelinating lesions of optic neuritis
• mice with EAE show typical myelinating/demyelinating lesions of optic neuritis
• 55 and 78% of transgenic mice immunized with 100 and 10 ug of MOG 35-55 without PT, respectively, develop optic nerve lesions
|
blepharitis
(
J:83278
)
|
• mice without EAE develop superficial inflammation around the eyelids; this is unilateral and not observed in wild-type littermates during up to 1 year observation
|
hematopoietic system
|
• CD4/CD8 single positive ratio in thymus of transgenic mice is biased toward CD4+ compartment
• analysis shows a skewing toward CD4+ T cells in spleens as well
|
cellular
|
• spleen cells from naive mice show increased proliferative response to myelin oligodendrocyte protein peptide 35-55 (MOG 35-55) compared to wild-type mice
|
homeostasis/metabolism
eyelid edema
(
J:83278
)
|
• mice without EAE show eyelid inflammation and eyelid swelling; this is unilateral and not observed in wild-type littermates during up to 1 year observation
|
craniofacial
eyelid edema
(
J:83278
)
|
• mice without EAE show eyelid inflammation and eyelid swelling; this is unilateral and not observed in wild-type littermates during up to 1 year observation
|
growth/size/body
eyelid edema
(
J:83278
)
|
• mice without EAE show eyelid inflammation and eyelid swelling; this is unilateral and not observed in wild-type littermates during up to 1 year observation
|


Analysis Tools